IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System

Purpose: To improve persistence of adoptively transferred T-cell receptor (TCR)–engineered T cells and durable clinical responses, we designed a clinical trial to transplant genetically-modified hematopoietic stem cells (HSCs) together with adoptive cell transfer of T cells both engineered to express an NY-ESO-1 TCR. Here, we report the preclinical studies performed to enable an investigational new drug (IND) application. Experimental Design: HSCs transduced with a lentiviral vector expressing NY-ESO-1 TCR and the PET reporter/suicide gene HSV1-sr39TK and T cells transduced with a retroviral vector expressing NY-ESO-1 TCR were coadministered to myelodepleted HLA-A2/Kb mice within a formal Good Laboratory Practice (GLP)–compliant study to demonstrate safety, persistence, and HSC differentiation into all blood lineages. Non-GLP experiments included assessment of transgene immunogenicity and in vitro viral insertion safety studies. Furthermore, Good Manufacturing Practice (GMP)–compliant cell production qualification runs were performed to establish the manufacturing protocols for clinical use. Results: TCR genetically modified and ex vivo–cultured HSCs differentiated into all blood subsets in vivo after HSC transplantation, and coadministration of TCR-transduced T cells did not result in increased toxicity. The expression of NY-ESO-1 TCR and sr39TK transgenes did not have a detrimental effect on gene-modified HSC's differentiation to all blood cell lineages. There was no evidence of genotoxicity induced by the lentiviral vector. GMP batches of clinical-grade transgenic cells produced during qualification runs had adequate stability and functionality. Conclusions: Coadministration of HSCs and T cells expressing an NY-ESO-1 TCR is safe in preclinical models. The results presented in this article led to the FDA approval of IND 17471.

[1]  David A. Williams,et al.  Hematopoietic Stem‐Cell Gene Therapy for Cerebral Adrenoleukodystrophy , 2017, The New England journal of medicine.

[2]  S. Rosenberg,et al.  Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David Baltimore,et al.  Generation of mature T cells from human hematopoietic stem/progenitor cells in artificial thymic organoids , 2017, Nature Methods.

[4]  G. Veres,et al.  Gene Therapy in a Patient with Sickle Cell Disease: Brief Report , 2017, The New England journal of medicine.

[5]  D. Elashoff,et al.  Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy , 2015, Human vaccines & immunotherapeutics.

[6]  J. Davies,et al.  Gene Therapy in a Patient with Sickle Cell Disease. , 2017, The New England journal of medicine.

[7]  L. Notarangelo,et al.  Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency , 2016, Science Translational Medicine.

[8]  K. Patel,et al.  Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers , 2016, Journal of immunotherapy.

[9]  M. Kamata,et al.  HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  J. E. Brewer,et al.  NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.

[11]  Frederic D Bushman,et al.  Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. , 2015, JAMA.

[12]  O. Witte,et al.  Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells , 2015, Proceedings of the National Academy of Sciences.

[13]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[14]  Michael L Kaufman,et al.  HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. , 2014, Cancer research.

[15]  J. Passweg,et al.  Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  K. Cornetta,et al.  Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma , 2014, Clinical Cancer Research.

[17]  Phyu P Aung,et al.  Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. , 2014, Human pathology.

[18]  H. Pircher,et al.  Immunotherapy with TCR-Redirected T Cells: Comparison of TCR-Transduced and TCR-Engineered Hematopoietic Stem Cell–Derived T Cells , 2014, The Journal of Immunology.

[19]  D. Elashoff,et al.  Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. , 2013, Human gene therapy.

[20]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[21]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[22]  O. Yang,et al.  Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Michael L Kaufman,et al.  Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  M. Raffeld,et al.  NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis , 2012, Modern Pathology.

[25]  O. Yang,et al.  In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells , 2012, PLoS pathogens.

[26]  D. Baltimore,et al.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells , 2011, Proceedings of the National Academy of Sciences.

[27]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[28]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Cornetta,et al.  Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. , 2010, The Journal of clinical investigation.

[30]  O. Yang,et al.  Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice , 2009, PloS one.

[31]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[32]  A. Schambach,et al.  Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[34]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[35]  Bent K. Jakobsen,et al.  Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions , 2008, The Journal of Immunology.

[36]  A. Schambach,et al.  Physiological promoters reduce the genotoxic risk of integrating gene vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[38]  A. Schambach,et al.  Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors , 2006, Gene Therapy.

[39]  Christof von Kalle,et al.  and insertional genotoxicity Cell culture assays reveal the importance of retroviral vector design for , 2006 .

[40]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[41]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[42]  D. Baltimore,et al.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[44]  R. Chesnut,et al.  Analysis of the HLArestricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex , 2003 .

[45]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[46]  D. Baltimore,et al.  Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Nolte,et al.  Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non‐Hodgkin's lymphoma , 2000, British journal of haematology.

[48]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[49]  K. Weinberg,et al.  Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency , 1995, Nature Medicine.

[50]  K. Weinberg,et al.  Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells , 1995, Journal of virology.

[51]  A. Vitiello,et al.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex , 1991, The Journal of experimental medicine.

[52]  W. Ostertag,et al.  Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.